US7026448B2
(en)
*
|
1998-09-01 |
2006-04-11 |
Genentech, Inc. |
Secreted and transmembrane polypeptides and nucleic acids encoding the same
|
DE19951360A1
(de)
*
|
1999-10-26 |
2001-05-03 |
Aventis Pharma Gmbh |
Substituierte Indole
|
JP2001131151A
(ja)
*
|
1999-11-02 |
2001-05-15 |
Shionogi & Co Ltd |
オレフィン誘導体の新規用途
|
ES2305125T3
(es)
|
2000-10-26 |
2008-11-01 |
Amgen Inc. |
Agentes anti-inflamatorios.
|
DE10115073A1
(de)
*
|
2001-03-27 |
2002-10-10 |
Procorde Gmbh |
Verwendung von Inhibitoren von IKK-ß und Verfahren zum Auffinden solcher Inhibitoren
|
RU2003131693A
(ru)
*
|
2001-03-28 |
2005-05-10 |
Бристол-Маерс Сквибб Компани (Us) |
Новые ингибиторы тирозин киназ
|
CA2445515A1
(en)
*
|
2001-05-04 |
2002-11-04 |
Paratek Pharmaceuticals, Inc. |
Transcription factor modulating compounds and methods of use thereof
|
US7405235B2
(en)
*
|
2001-05-04 |
2008-07-29 |
Paratek Pharmaceuticals, Inc. |
Transcription factor modulating compounds and methods of use thereof
|
WO2002101182A2
(en)
*
|
2001-06-13 |
2002-12-19 |
Billiton Sa Limited |
Solvent extraction mixture comprising substituted imidazole or benzimidazole for the separation of groups of base metals
|
WO2002101101A2
(en)
*
|
2001-06-13 |
2002-12-19 |
Billiton Sa Limited |
Solvent extraction mixture comprising substituted imidazole or benzimidazole for the purification of base metals
|
US8124625B2
(en)
|
2001-09-14 |
2012-02-28 |
Shionogi & Co., Ltd. |
Method of enhancing the expression of apolipoprotein AI using olefin derivatives
|
US6897208B2
(en)
|
2001-10-26 |
2005-05-24 |
Aventis Pharmaceuticals Inc. |
Benzimidazoles
|
FR2831537B1
(fr)
*
|
2001-10-26 |
2008-02-29 |
Aventis Pharma Sa |
Nouveaux derives de benzimidazoles, leur procede de preparation, leur application a titre de medicament, compositions pharmaceutiques et nouvelle utilisation
|
JP5039268B2
(ja)
*
|
2001-10-26 |
2012-10-03 |
アベンティス・ファーマスーティカルズ・インコーポレイテツド |
ベンゾイミダゾールおよび類縁体および蛋白キナーゼ阻害剤としてのその使用
|
FR2831536A1
(fr)
*
|
2001-10-26 |
2003-05-02 |
Aventis Pharma Sa |
Nouveaux derives de benzimidazoles, leur procede de preparation, leur application a titre de medicament, compositions pharmaceutiques et nouvelle utilisation notamment comme inhibiteurs de kdr
|
AR037641A1
(es)
|
2001-12-05 |
2004-11-17 |
Tularik Inc |
Moduladores de inflamacion
|
NZ533958A
(en)
|
2002-01-07 |
2007-09-28 |
Eisai Co Ltd |
Deazapurines and uses thereof
|
JP2005516054A
(ja)
*
|
2002-01-29 |
2005-06-02 |
ワイス |
コネキシンヘミチャンネルを調節する組成物及びその方法
|
WO2003065534A1
(de)
|
2002-01-30 |
2003-08-07 |
Siemens Aktiengesellschaft |
Einrichtung zum kurzschliessen von zwei elektrischen leitungen zum abbau einer potentialdifferenz
|
SG159380A1
(en)
*
|
2002-02-06 |
2010-03-30 |
Vertex Pharma |
Heteroaryl compounds useful as inhibitors of gsk-3
|
US7528161B2
(en)
*
|
2002-05-31 |
2009-05-05 |
Michigan State University |
NF-kappaB inhibitors and uses thereof
|
US20080114015A1
(en)
*
|
2002-05-31 |
2008-05-15 |
Board Of Trustees Of Michigan State University |
NF-kB inhibitors and uses thereof
|
US6974870B2
(en)
|
2002-06-06 |
2005-12-13 |
Boehringer Ingelheim Phamaceuticals, Inc. |
Substituted 3-amino-thieno [2,3-b]pyridine-2-carboxylic acid amide compounds and processes for preparing and their uses
|
NZ537394A
(en)
|
2002-06-06 |
2006-12-22 |
Boehringer Ingelheim Pharma |
Substituted 3-amino-thieno[2,3-b]pyridine-2-carboxylic acid amide compounds and processes for preparing and their uses
|
WO2004017997A1
(ja)
*
|
2002-08-06 |
2004-03-04 |
Toray Industries, Inc. |
腎疾患治療又は予防剤及び腎疾患の診断方法
|
US7122580B2
(en)
*
|
2002-08-09 |
2006-10-17 |
Transtech Pharma, Inc. |
Aryl and heteroaryl compounds and methods to modulate coagulation
|
DE10237723A1
(de)
*
|
2002-08-17 |
2004-07-08 |
Aventis Pharma Deutschland Gmbh |
Verwendung von IKappaB-Kinase Inhibitoren in der Schmerztherapie
|
DE10237722A1
(de)
|
2002-08-17 |
2004-08-19 |
Aventis Pharma Deutschland Gmbh |
Indol- oder Benzimidazolderivate zur Modulation der IKappaB-Kinase
|
US7462638B2
(en)
*
|
2002-08-17 |
2008-12-09 |
Sanofi-Aventis Deutschland Gmbh |
Use of IκB-kinase inhibitors in pain therapy
|
DE10238002A1
(de)
*
|
2002-08-20 |
2004-03-04 |
Merck Patent Gmbh |
Benzimidazolderivate
|
WO2004026864A1
(en)
*
|
2002-09-17 |
2004-04-01 |
Warner-Lambert Company Llc |
Heterocyclic substituted piperazines for the treatment of schizophrenia
|
JP2006512313A
(ja)
|
2002-10-31 |
2006-04-13 |
アムジェン インコーポレイテッド |
抗炎症剤
|
WO2004041277A1
(en)
*
|
2002-11-01 |
2004-05-21 |
Merck & Co., Inc. |
Carbonylamino-benzimidazole derivatives as androgen receptor modulators
|
US7640843B2
(en)
|
2003-01-24 |
2010-01-05 |
Kraft Foods R & D, Inc. |
Cartridge and method for the preparation of beverages
|
US20050004164A1
(en)
*
|
2003-04-30 |
2005-01-06 |
Caggiano Thomas J. |
2-Cyanopropanoic acid amide and ester derivatives and methods of their use
|
US20050256132A1
(en)
*
|
2003-04-30 |
2005-11-17 |
Wyeth |
Use of ER selective NF-kB inhibitors for the treatment of sepsis
|
JP2007515937A
(ja)
*
|
2003-05-08 |
2007-06-21 |
ベス イスラエル デアコネス メディカル センター インコーポレイティッド |
NF−κBの調節機構
|
TWI372050B
(en)
*
|
2003-07-03 |
2012-09-11 |
Astex Therapeutics Ltd |
(morpholin-4-ylmethyl-1h-benzimidazol-2-yl)-1h-pyrazoles
|
US7208601B2
(en)
*
|
2003-08-08 |
2007-04-24 |
Mjalli Adnan M M |
Aryl and heteroaryl compounds, compositions, and methods of use
|
WO2005014532A1
(en)
*
|
2003-08-08 |
2005-02-17 |
Transtech Pharma, Inc. |
Aryl and heteroaryl compounds, compositions and methods of use
|
JP2007501844A
(ja)
*
|
2003-08-08 |
2007-02-01 |
トランス テック ファーマ,インコーポレイテッド |
アリール及びヘテロアリール化合物、組成物並びに使用方法
|
PT1682553E
(pt)
*
|
2003-09-08 |
2010-07-29 |
Aventis Pharma Inc |
Tienopirazoles
|
US20070208166A1
(en)
*
|
2003-10-24 |
2007-09-06 |
Exelixis, Inc. |
Tao Kinase Modulators And Method Of Use
|
WO2005056562A1
(en)
*
|
2003-12-05 |
2005-06-23 |
Boehringer Ingelheim Pharmaceuticals, Inc. |
Substituted 3-amino-thieno[2,3-b] pyridine-2-carboxylic acid amide compounds as ikk inhibitors
|
CA2562763A1
(en)
|
2004-04-23 |
2006-07-20 |
Paratek Pharmaceuticals, Inc. |
Transcription factor modulating compounds and methods of use thereof
|
US7425580B2
(en)
|
2004-05-19 |
2008-09-16 |
Wyeth |
(Diaryl-methyl)-malononitriles and their use as estrogen receptor ligands
|
PE20060373A1
(es)
|
2004-06-24 |
2006-04-29 |
Smithkline Beecham Corp |
Derivados 3-piperidinil-7-carboxamida-indazol como inhibidores de la actividad cinasa de ikk2
|
US8110573B2
(en)
*
|
2004-12-30 |
2012-02-07 |
Astex Therapeutics Limited |
Pyrazole compounds that modulate the activity of CDK, GSK and aurora kinases
|
EP1836199A1
(en)
*
|
2004-12-30 |
2007-09-26 |
Astex Therapeutics Limited |
Thiazole and isothiazole derivatives that modulate the activity of cdk, gsk and aurora kinases
|
EP2457901A1
(en)
*
|
2005-03-14 |
2012-05-30 |
High Point Pharmaceuticals, LLC |
Benzazole derivatives, compositions, and methods of use as B-secretase inhibitors
|
DK1863801T3
(da)
*
|
2005-03-30 |
2010-11-15 |
Takeda Pharmaceutical |
Benzimidazolderivat og anvendelse deraf
|
TWI370820B
(en)
*
|
2005-04-27 |
2012-08-21 |
Takeda Pharmaceutical |
Fused heterocyclic compounds
|
KR20080021077A
(ko)
|
2005-06-30 |
2008-03-06 |
스미스클라인 비참 코포레이션 |
화합물
|
US8063071B2
(en)
|
2007-10-31 |
2011-11-22 |
GlaxoSmithKline, LLC |
Chemical compounds
|
US8093401B2
(en)
|
2005-08-04 |
2012-01-10 |
Sirtris Pharmaceuticals, Inc. |
Sirtuin modulating compounds
|
US7855289B2
(en)
|
2005-08-04 |
2010-12-21 |
Sirtris Pharmaceuticals, Inc. |
Sirtuin modulating compounds
|
CA2617532A1
(en)
|
2005-08-04 |
2007-02-15 |
Sirtris Pharmaceuticals, Inc. |
Imidazo [2,1-b] thiazole derivatives as sirtuin modulating compounds
|
US8088928B2
(en)
|
2005-08-04 |
2012-01-03 |
Sirtris Pharmaceuticals, Inc. |
Sirtuin modulating compounds
|
JP2009001495A
(ja)
*
|
2005-10-13 |
2009-01-08 |
Taisho Pharmaceutical Co Ltd |
2−アリール−ベンゾイミダゾール−5−カルボキサミド誘導体
|
US8399442B2
(en)
*
|
2005-12-30 |
2013-03-19 |
Astex Therapeutics Limited |
Pharmaceutical compounds
|
WO2007084728A2
(en)
*
|
2006-01-19 |
2007-07-26 |
Abbott Laboratories |
2-imino-benzimidazoles
|
PT2007752E
(pt)
|
2006-03-31 |
2010-10-18 |
Janssen Pharmaceutica Nv |
Benzoimidazol-2-il pirimidinas e pirazinas como moduladores do receptor de histamina h4
|
JP2009532367A
(ja)
*
|
2006-03-31 |
2009-09-10 |
ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ |
ヒスタミンh4受容体のモジュレーターとしてのベンゾイミダゾール−2−イルピリジン
|
CA2653654A1
(en)
|
2006-06-06 |
2007-12-21 |
Boehringer Ingelheim International Gmbh |
Substituted 3-amino-thieno[2,3-b] pyridine-2-carboxamide compounds, their preparation and use
|
AU2007351886A1
(en)
*
|
2006-06-23 |
2008-10-30 |
Paratek Pharmaceuticals, Inc. |
Transcription factor modulating compounds and methods of use thereof
|
EP2049119A2
(en)
*
|
2006-06-29 |
2009-04-22 |
Astex Therapeutics Limited |
Pharmaceutical combinations of 1-cyclopropyl-3-[3-(5-morphoolin-4-ylmethyl-1h-benzoimidazol-2-yl)-1h-1-pyrazol-4-yl]-urea
|
EP2043635A2
(en)
*
|
2006-06-29 |
2009-04-08 |
Astex Therapeutics Limited |
Pharmaceutical combinations
|
BRPI0715160A2
(pt)
|
2006-08-08 |
2013-06-11 |
Sanofi Aventis |
imidazolidina-2,4-dionas substituÍdas por arilamimoaril-alquil-, processo para preparÁ-las, medicamentos compeendendo estes compostos, e seu uso
|
CA2663100A1
(en)
*
|
2006-09-07 |
2008-03-13 |
Biogen Idec Ma Inc. |
Indazole derivatives as modulators of interleukin-1 receptor-associated kinase
|
PE20080888A1
(es)
*
|
2006-10-18 |
2008-08-26 |
Novartis Ag |
COMPUESTOS HETEROCICLICOS COMO INHIBIDORES DE LA ACIL-TRANSFERASA DE ACIL-CoA-DIACIL-GLICEROL 1 (DGAT1)
|
AR065804A1
(es)
|
2007-03-23 |
2009-07-01 |
Smithkline Beecham Corp |
Compuesto de indol carboxamida, composicion farmaceutica que lo comprende y uso de dicho compuesto para preparar un medicamento
|
CA2681813A1
(en)
*
|
2007-03-27 |
2009-01-08 |
Paratek Pharmaceuticals, Inc. |
Transcription factor modulating compounds and methods of use thereof
|
CL2008001822A1
(es)
|
2007-06-20 |
2009-03-13 |
Sirtris Pharmaceuticals Inc |
Compuestos derivados de tiazolo[5,4-b]piridina; composicion farmaceutica que comprende a dichos compuestos; y uso del compuesto en el tratamiento de la resistencia a la insulina, sindrome metabolico, diabetes, entre otras.
|
EP2025674A1
(de)
|
2007-08-15 |
2009-02-18 |
sanofi-aventis |
Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
|
NZ583970A
(en)
|
2007-10-11 |
2011-04-29 |
Univ California |
Compositions and methods of inhibiting n-acylethanolamine-hydrolyzing acid amidase
|
US8084466B2
(en)
|
2007-12-18 |
2011-12-27 |
Janssen Pharmaceutica Nv |
Bicyclic heteroaryl-substituted imidazoles as modulators of the histamine H4 receptor
|
US11969501B2
(en)
|
2008-04-21 |
2024-04-30 |
Dompé Farmaceutici S.P.A. |
Auris formulations for treating otic diseases and conditions
|
KR20190026056A
(ko)
|
2008-04-21 |
2019-03-12 |
오토노미, 인코포레이티드 |
귀 질환 및 병태를 치료하기 위한 귀 조제물
|
WO2009134847A1
(en)
*
|
2008-04-30 |
2009-11-05 |
Smithkline Beecham Corporation |
Prolyl hydroxylase inhibitors
|
US9371311B2
(en)
|
2008-06-30 |
2016-06-21 |
Janssen Pharmaceutica Nv |
Benzoimidazol-2-yl pyrimidine derivatives
|
JP5758292B2
(ja)
*
|
2008-07-03 |
2015-08-05 |
サートリス ファーマシューティカルズ, インコーポレイテッド |
サーチュイン調節薬としてのベンズイミダゾールおよび関連する類似体
|
UY31968A
(es)
|
2008-07-09 |
2010-01-29 |
Sanofi Aventis |
Nuevos derivados heterocíclicos, sus procesos para su preparación, y sus usos terapéuticos
|
WO2010068601A1
(en)
|
2008-12-08 |
2010-06-17 |
Sanofi-Aventis |
A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof
|
UA104447C2
(ru)
|
2008-12-19 |
2014-02-10 |
Сіртріз Фармасьютікалз, Інк. |
Тиазолопиридиновые соединения, модулирующие сиртуин
|
WO2010102968A1
(en)
|
2009-03-10 |
2010-09-16 |
Glaxo Group Limited |
Indole derivatives as ikk2 inhibitors
|
US20110059962A1
(en)
*
|
2009-04-22 |
2011-03-10 |
Alekshun Michael N |
Transcription factor modulating compounds and methods of use thereof
|
JP5763072B2
(ja)
|
2009-08-10 |
2015-08-12 |
サミュメッド リミテッド ライアビリティ カンパニー |
Wntシグナル経路のインダゾール阻害剤およびその治療的使用
|
CN102595899A
(zh)
*
|
2009-08-10 |
2012-07-18 |
埃皮瑟瑞克斯有限公司 |
作为wnt/b-联蛋白信号传导途径抑制剂的吲唑及其治疗用途
|
US8785608B2
(en)
|
2009-08-26 |
2014-07-22 |
Sanofi |
Crystalline heteroaromatic fluoroglycoside hydrates, pharmaceuticals comprising these compounds and their use
|
WO2011045415A2
(en)
*
|
2009-10-15 |
2011-04-21 |
Guerbet |
New imaging agents and their use for the diagnostic in vivo of neurodegenerative diseases, notably alzheimer's disease and derivative diseases
|
BR112012018413A2
(pt)
|
2009-12-21 |
2016-08-09 |
Samumed Llc |
1h-pirazol[3,4-b]piridinas e usos terapêuticos dos mesmos.
|
DK2536285T3
(en)
*
|
2010-02-18 |
2018-07-16 |
Vtv Therapeutics Llc |
Substituted fused imidazole derivatives, pharmaceutical compositions and methods for their use
|
US8759535B2
(en)
|
2010-02-18 |
2014-06-24 |
High Point Pharmaceuticals, Llc |
Substituted fused imidazole derivatives, pharmaceutical compositions, and methods of use thereof
|
WO2011107494A1
(de)
|
2010-03-03 |
2011-09-09 |
Sanofi |
Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
|
EP2582709B1
(de)
|
2010-06-18 |
2018-01-24 |
Sanofi |
Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen
|
US8530413B2
(en)
|
2010-06-21 |
2013-09-10 |
Sanofi |
Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
|
TW201221505A
(en)
|
2010-07-05 |
2012-06-01 |
Sanofi Sa |
Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
|
TW201215388A
(en)
|
2010-07-05 |
2012-04-16 |
Sanofi Sa |
(2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
|
TW201215387A
(en)
|
2010-07-05 |
2012-04-16 |
Sanofi Aventis |
Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
|
US8871758B2
(en)
|
2011-03-08 |
2014-10-28 |
Sanofi |
Tetrasubstituted oxathiazine derivatives, method for producing them, their use as medicine and drug containing said derivatives and the use thereof
|
WO2012120058A1
(de)
|
2011-03-08 |
2012-09-13 |
Sanofi |
Mit benzyl- oder heteromethylengruppen substituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
|
EP2683705B1
(de)
|
2011-03-08 |
2015-04-22 |
Sanofi |
Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
|
WO2012120052A1
(de)
|
2011-03-08 |
2012-09-13 |
Sanofi |
Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
|
WO2012120055A1
(de)
|
2011-03-08 |
2012-09-13 |
Sanofi |
Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
|
WO2012120053A1
(de)
|
2011-03-08 |
2012-09-13 |
Sanofi |
Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
|
US8895547B2
(en)
|
2011-03-08 |
2014-11-25 |
Sanofi |
Substituted phenyl-oxathiazine derivatives, method for producing them, drugs containing said compounds and the use thereof
|
US8809324B2
(en)
|
2011-03-08 |
2014-08-19 |
Sanofi |
Substituted phenyl-oxathiazine derivatives, method for producing them, drugs containing said compounds and the use thereof
|
EP2683698B1
(de)
|
2011-03-08 |
2017-10-04 |
Sanofi |
Mit adamantan- oder noradamantan substituierte benzyl-oxathiazinderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
|
US9856534B2
(en)
|
2011-04-29 |
2018-01-02 |
Emory University |
Selecting use of proteasome inhibitors based on NF-κB2 sequence
|
WO2013037390A1
(en)
|
2011-09-12 |
2013-03-21 |
Sanofi |
6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
|
PL2755483T3
(pl)
|
2011-09-14 |
2019-06-28 |
Samumed, Llc |
Indazolo-3-karboksyamidy i ich zastosowanie jako inhibitorów szlaków sygnalizacji WNT/B-kateniny
|
WO2013045413A1
(en)
|
2011-09-27 |
2013-04-04 |
Sanofi |
6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
|
CA2856522C
(en)
|
2011-11-22 |
2020-10-27 |
The Regents Of The University Of California |
Disubstituted beta-lactones as inhibitors of n-acylethanolamine acid amidase (naaa)
|
PH12017500997A1
(en)
|
2012-04-04 |
2018-02-19 |
Samumed Llc |
Indazole inhibitors of the wnt signal pathway and therapeutic uses thereof
|
MA37577B1
(fr)
|
2012-05-04 |
2018-05-31 |
Samumed Llc |
1h-pyrazolo[3,4-b]pyridines et leurs utilisations thérapeutiques
|
JP6355648B2
(ja)
|
2013-01-08 |
2018-07-11 |
サミュメッド リミテッド ライアビリティ カンパニー |
Wntシグナル伝達経路の3−(ベンゾイミダゾール−2−イル)−インダゾール阻害剤およびそれらの治療的使用
|
MY180726A
(en)
|
2013-03-06 |
2020-12-08 |
Janssen Pharmaceutica Nv |
Benzoimidazol-2-yl pyrimidine modulators of the histamine h4 receptor
|
WO2014144547A2
(en)
|
2013-03-15 |
2014-09-18 |
The Regents Of The University Of California |
Amide derivatives of lactam based n-acylethanolamine acid amidase (naaa) inhibitors
|
WO2014144836A2
(en)
|
2013-03-15 |
2014-09-18 |
The Regents Of The University Of California |
Carbamate derivatives of lactam based n-acylethanolamine acid amidase (naaa) inhibitors
|
EP3087054A4
(en)
|
2013-12-27 |
2017-10-25 |
Novus International Inc. |
Ethoxylated surfactants
|
SG11201606080SA
(en)
|
2014-02-03 |
2016-08-30 |
Vitae Pharmaceuticals Inc |
Dihydropyrrolopyridine inhibitors of ror-gamma
|
WO2016040185A1
(en)
|
2014-09-08 |
2016-03-17 |
Samumed, Llc |
2-(1h-indazol-3-yl)-3h-imidazo[4,5-b]pyridine and therapeutic uses thereof
|
WO2016040190A1
(en)
|
2014-09-08 |
2016-03-17 |
Samumed, Llc |
3-(3h-imidazo[4,5-b]pyridin-2-yl)-1h-pyrazolo[3,4-b]pyridine and therapeutic uses thereof
|
WO2016040182A1
(en)
|
2014-09-08 |
2016-03-17 |
Samumed, Llc |
2-(1h-indazol-3-yl)-1h-imidazo[4,5-c]pyridine and therapeutic uses thereof
|
WO2016040180A1
(en)
|
2014-09-08 |
2016-03-17 |
Samumed, Llc |
3-(1h-benzo[d]imidazol-2-yl)-1h-pyrazolo[3,4-c]pyridine and therapeutic uses thereof
|
WO2016040181A1
(en)
|
2014-09-08 |
2016-03-17 |
Samumed, Llc |
3-(1h-imidazo[4,5-c]pyridin-2-yl)-1h-pyrazolo[3,4-c]pyridine and therapeutic uses thereof
|
WO2016040193A1
(en)
|
2014-09-08 |
2016-03-17 |
Samumed, Llc |
3-(1h-imidazo[4,5-c]pyridin-2-yl)-1h-pyrazolo[3,4-b]pyridine and therapeutic uses thereof
|
WO2016040188A1
(en)
|
2014-09-08 |
2016-03-17 |
Samumed, Llc |
3-(3h-imidazo[4,5-c]pyridin-2-yl)-1h-pyrazolo[3,4-c]pyridine and therapeutic uses thereof
|
WO2016040184A1
(en)
|
2014-09-08 |
2016-03-17 |
Samumed, Llc |
3-(3h-imidazo[4,5-b]pyridin-2-yl)-1h-pyrazolo[3,4-c]pyridine and therapeutic uses thereof
|
WO2016089648A1
(en)
|
2014-12-01 |
2016-06-09 |
Vtv Therapeutics Llc |
Bach 1 inhibitors in combination with nrf2 activators and pharmaceutical compositions thereof
|
US10166218B2
(en)
|
2015-08-03 |
2019-01-01 |
Samumed, Llc |
3-(1H-indol-2-yl)-1H-pyrazolo[3,4-C]pyridines and therapeutic uses thereof
|
US10392383B2
(en)
|
2015-08-03 |
2019-08-27 |
Samumed, Llc |
3-(1H-benzo[d]imidazol-2-yl)-1H-pyrazolo[4,3-b]pyridines and therapeutic uses thereof
|
WO2017023975A1
(en)
|
2015-08-03 |
2017-02-09 |
Samumed, Llc. |
3-(1h-pyrrolo[2,3-c]pyridin-2-yl)-1h-pyrazolo[3,4-c]pyridines and therapeutic uses thereof
|
US10329309B2
(en)
|
2015-08-03 |
2019-06-25 |
Samumed, Llc |
3-(3H-imidazo[4,5-B]pyridin-2-yl)-1H-pyrazolo[4,3-B]pyridines and therapeutic uses thereof
|
US10519169B2
(en)
|
2015-08-03 |
2019-12-31 |
Samumed, Llc |
3-(1H-pyrrolo[2,3-C]pyridin-2-yl)-1 H-pyrazolo[4,3-B]pyridines and therapeutic uses thereof
|
US10231956B2
(en)
|
2015-08-03 |
2019-03-19 |
Samumed, Llc |
3-(1H-pyrrolo[3,2-C]pyridin-2-YL)-1 H-pyrazolo[4,3-B]pyridines and therapeutic uses thereof
|
WO2017024021A1
(en)
|
2015-08-03 |
2017-02-09 |
Samumed, Llc |
3-(1h-pyrrolo[2,3-b]pyridin-2-yl)-1h-indazoles and therapeutic uses thereof
|
WO2017024004A1
(en)
|
2015-08-03 |
2017-02-09 |
Samumed, Llc. |
3-(1h-pyrrolo[2,3-b]pyridin-2-yl)-1h-pyrazolo[4,3-b]pyridines and therapeutic uses thereof
|
US10206908B2
(en)
|
2015-08-03 |
2019-02-19 |
Samumed, Llc |
3-(1H-pyrrolo[3,2-C]pyridin-2-YL)-1H-pyrazolo[3,4-C]pyridines and therapeutic uses thereof
|
US10226448B2
(en)
|
2015-08-03 |
2019-03-12 |
Samumed, Llc |
3-(1H-pyrrolo[3,2-C]pyridin-2-yl)-1H-pyrazolo[3,4-B]pyridines and therapeutic uses thereof
|
WO2017023980A1
(en)
|
2015-08-03 |
2017-02-09 |
Samumed, Llc. |
3-(1h-pyrrolo[2,3-b]pyridin-2-yl)-1h-pyrazolo[3,4-c]pyridines and therapeutic uses thereof
|
WO2017023996A1
(en)
|
2015-08-03 |
2017-02-09 |
Samumed, Llc. |
3-(1h-pyrrolo[2,3-b]pyridin-2-yl)-1h-pyrazolo[3,4-b]pyridines and therapeutic uses thereof
|
WO2017024010A1
(en)
|
2015-08-03 |
2017-02-09 |
Samumed, Llc. |
3-(1h-pyrrolo[3,2-c]pyridin-2-yl)-1h-indazoles and therapeutic uses thereof
|
WO2017023972A1
(en)
|
2015-08-03 |
2017-02-09 |
Samumed, Llc. |
3-(1h-imidazo[4,5-c]pyridin-2-yl)-1h-pyrazolo[4,3-b]pyridines and therapeutic uses thereof
|
US10604512B2
(en)
|
2015-08-03 |
2020-03-31 |
Samumed, Llc |
3-(1H-indol-2-yl)-1H-indazoles and therapeutic uses thereof
|
WO2017023993A1
(en)
|
2015-08-03 |
2017-02-09 |
Samumed, Llc. |
3-(1h-indol-2-yl)-1h-pyrazolo[4,3-b]pyridines and therapeutic uses thereof
|
WO2017023988A1
(en)
|
2015-08-03 |
2017-02-09 |
Samumed, Llc. |
3-(3h-imidazo[4,5-c]pyridin-2-yl)-1h-pyrazolo[4,3-b]pyridines and therapeutic uses thereof
|
US10899757B2
(en)
|
2015-11-06 |
2021-01-26 |
Samumed, Llc |
2-(1H-indazol-3-yl)-3H-imidazo[4,5-C]pyridines and their anti-inflammatory uses thereof
|
EP3377482B1
(en)
|
2015-11-20 |
2021-05-12 |
Vitae Pharmaceuticals, LLC |
Modulators of ror-gamma
|
TWI757266B
(zh)
*
|
2016-01-29 |
2022-03-11 |
美商維它藥物有限責任公司 |
ROR-γ調節劑
|
US10590084B2
(en)
|
2016-03-09 |
2020-03-17 |
Blade Therapeutics, Inc. |
Cyclic keto-amide compounds as calpain modulators and methods of production and use thereof
|
MD3464285T2
(ro)
|
2016-06-01 |
2023-01-31 |
Biosplice Therapeutics Inc |
Procedeu pentru prepararea N-(5-(3-(7-(3-fluorfenil)-3H-imidazo[4,5-c]piridin-2-il)-1H-indazol-5-il)piridin-3-il)-3-metilbutanamidei
|
KR20190024983A
(ko)
|
2016-06-29 |
2019-03-08 |
오토노미, 인코포레이티드 |
트리글리세라이드 귀 제제 및 이의 용도
|
WO2018009417A1
(en)
|
2016-07-05 |
2018-01-11 |
Blade Therapeutics, Inc. |
Calpain modulators and therapeutic uses thereof
|
JP7278945B2
(ja)
*
|
2016-09-20 |
2023-05-22 |
サントル レオン ベラール |
抗癌剤としてのベンゾイミダゾール誘導体
|
US10934261B2
(en)
|
2016-09-28 |
2021-03-02 |
Blade Therapeutics, Inc. |
Calpain modulators and therapeutic uses thereof
|
MX2019004616A
(es)
|
2016-10-21 |
2019-11-21 |
Samumed Llc |
Métodos de uso de indazol-3-carboxamidas y su uso como inhibidores de la ruta de señalización de wnt/b-catenina.
|
MA46696A
(fr)
|
2016-11-07 |
2019-09-11 |
Samumed Llc |
Formulations injectables à dose unique prêtes à l'emploi
|
AR112461A1
(es)
|
2017-07-24 |
2019-10-30 |
Vitae Pharmaceuticals Inc |
PROCESOS PARA LA PRODUCCIÓN DE SALES Y FORMAS CRISTALINAS DE INHIBIDORES DE RORg
|
WO2019018975A1
(en)
|
2017-07-24 |
2019-01-31 |
Vitae Pharmaceuticals, Inc. |
INHIBITORS OF ROR GAMMA
|
US10584306B2
(en)
|
2017-08-11 |
2020-03-10 |
Board Of Regents Of The University Of Oklahoma |
Surfactant microemulsions
|
US11447482B1
(en)
|
2019-02-14 |
2022-09-20 |
KUDA Therapeutics, Inc. |
Imidazopyridine and oxazolopyridine derivatives and analogs thereof, methods of preparation thereof, methods of HIF-2A pathway inhibition, and induction of ferroptosis
|